nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycine—PIPOX—psoriasis	0.837	1	CbGaD
Glycine—GARS—Cytosolic tRNA aminoacylation—TARS—psoriasis	0.0112	0.164	CbGpPWpGaD
Glycine—GARS—tRNA Aminoacylation—TARS—psoriasis	0.00714	0.105	CbGpPWpGaD
Glycine—GARS—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.0025	0.52	CbGdCrCtD
Glycine—Toxicity to various agents—Mycophenolic acid—psoriasis	0.00232	0.0277	CcSEcCtD
Glycine—Pulmonary congestion—Mycophenolic acid—psoriasis	0.00219	0.0262	CcSEcCtD
Glycine—BAAT—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.002	0.0294	CbGpPWpGaD
Glycine—Toxicity to various agents—Cyclosporine—psoriasis	0.00187	0.0224	CcSEcCtD
Glycine—Respiratory tract congestion—Mycophenolic acid—psoriasis	0.00181	0.0217	CcSEcCtD
Glycine—Blindness transient—Methotrexate—psoriasis	0.00162	0.0194	CcSEcCtD
Glycine—Lightheadedness—Beclomethasone—psoriasis	0.00145	0.0173	CcSEcCtD
Glycine—ALAS1—Transcriptional activation of mitochondrial biogenesis—CARM1—psoriasis	0.00133	0.0195	CbGpPWpGaD
Glycine—Acidosis—Mycophenolic acid—psoriasis	0.0012	0.0143	CcSEcCtD
Glycine—ALAS1—Mitochondrial biogenesis—CARM1—psoriasis	0.00115	0.0168	CbGpPWpGaD
Glycine—Electrolyte imbalance—Hydrocortisone—psoriasis	0.00114	0.0136	CcSEcCtD
Glycine—GLYATL1—Biological oxidations—CYP2S1—psoriasis	0.00113	0.0166	CbGpPWpGaD
Glycine—GLYAT—Biological oxidations—CYP2S1—psoriasis	0.00113	0.0166	CbGpPWpGaD
Glycine—GLYATL2—Biological oxidations—CYP2S1—psoriasis	0.00113	0.0166	CbGpPWpGaD
Glycine—GLYATL2—Metapathway biotransformation—CYP2S1—psoriasis	0.00111	0.0163	CbGpPWpGaD
Glycine—GLYATL1—Metapathway biotransformation—CYP2S1—psoriasis	0.00111	0.0163	CbGpPWpGaD
Glycine—GLYAT—Metapathway biotransformation—CYP2S1—psoriasis	0.00111	0.0163	CbGpPWpGaD
Glycine—Fluid overload—Mycophenolic acid—psoriasis	0.00106	0.0127	CcSEcCtD
Glycine—BAAT—Metapathway biotransformation—CYP2S1—psoriasis	0.00106	0.0156	CbGpPWpGaD
Glycine—SLC6A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00103	0.015	CbGpPWpGaD
Glycine—SLC6A9—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00103	0.015	CbGpPWpGaD
Glycine—Salivary hypersecretion—Acitretin—psoriasis	0.000977	0.0117	CcSEcCtD
Glycine—Electrolyte imbalance—Betamethasone—psoriasis	0.000973	0.0116	CcSEcCtD
Glycine—Electrolyte imbalance—Dexamethasone—psoriasis	0.000973	0.0116	CcSEcCtD
Glycine—GPR18—G alpha (i) signalling events—HCAR2—psoriasis	0.000973	0.0143	CbGpPWpGaD
Glycine—Acidosis—Mycophenolate mofetil—psoriasis	0.000943	0.0113	CcSEcCtD
Glycine—Polyuria—Calcitriol—psoriasis	0.000935	0.0112	CcSEcCtD
Glycine—Lung disorder—Mycophenolic acid—psoriasis	0.000935	0.0112	CcSEcCtD
Glycine—Pain—Calcipotriol—psoriasis	0.00087	0.0104	CcSEcCtD
Glycine—Thirst—Calcitriol—psoriasis	0.000863	0.0103	CcSEcCtD
Glycine—Fluid overload—Mycophenolate mofetil—psoriasis	0.00084	0.01	CcSEcCtD
Glycine—Encephalopathy—Cyclosporine—psoriasis	0.000834	0.00996	CcSEcCtD
Glycine—Encephalopathy—Mycophenolate mofetil—psoriasis	0.000814	0.00972	CcSEcCtD
Glycine—GPR18—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000773	0.0113	CbGpPWpGaD
Glycine—Visual disturbance—Acitretin—psoriasis	0.000771	0.00921	CcSEcCtD
Glycine—Visual disturbance—Fluocinolone Acetonide—psoriasis	0.000769	0.00919	CcSEcCtD
Glycine—Thirst—Acitretin—psoriasis	0.000768	0.00917	CcSEcCtD
Glycine—Dehydration—Calcitriol—psoriasis	0.000764	0.00912	CcSEcCtD
Glycine—Cardiovascular disorder—Mycophenolic acid—psoriasis	0.000753	0.009	CcSEcCtD
Glycine—Oedema—Tazarotene—psoriasis	0.00075	0.00896	CcSEcCtD
Glycine—Hypersensitivity—Calcipotriol—psoriasis	0.00075	0.00896	CcSEcCtD
Glycine—Lung disorder—Mycophenolate mofetil—psoriasis	0.000738	0.00882	CcSEcCtD
Glycine—GPR18—tendon—psoriasis	0.000735	0.116	CbGeAlD
Glycine—SHMT2—Folate Metabolism—CAT—psoriasis	0.00073	0.0107	CbGpPWpGaD
Glycine—SHMT2—Vitamin B12 Metabolism—CRP—psoriasis	0.000712	0.0105	CbGpPWpGaD
Glycine—SLC6A9—NRF2 pathway—TGFA—psoriasis	0.000705	0.0104	CbGpPWpGaD
Glycine—SLC6A5—NRF2 pathway—TGFA—psoriasis	0.000705	0.0104	CbGpPWpGaD
Glycine—SHMT2—Vitamin B12 Metabolism—APOE—psoriasis	0.000697	0.0102	CbGpPWpGaD
Glycine—Back pain—Beclomethasone—psoriasis	0.000686	0.0082	CcSEcCtD
Glycine—GCAT—skin of body—psoriasis	0.000679	0.107	CbGeAlD
Glycine—SHMT2—Folate Metabolism—IL4—psoriasis	0.000671	0.00984	CbGpPWpGaD
Glycine—SHMT2—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000655	0.00961	CbGpPWpGaD
Glycine—ALAS1—PPARA activates gene expression—CARM1—psoriasis	0.000649	0.00953	CbGpPWpGaD
Glycine—GSS—Biological oxidations—CYP2S1—psoriasis	0.000649	0.00952	CbGpPWpGaD
Glycine—Pain—Tazarotene—psoriasis	0.000642	0.00767	CcSEcCtD
Glycine—GSS—Metapathway biotransformation—CYP2S1—psoriasis	0.00064	0.00939	CbGpPWpGaD
Glycine—ALAS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000636	0.00933	CbGpPWpGaD
Glycine—Cardiovascular disorder—Cyclosporine—psoriasis	0.000609	0.00728	CcSEcCtD
Glycine—Cardiovascular disorder—Mycophenolate mofetil—psoriasis	0.000594	0.0071	CcSEcCtD
Glycine—GPR18—GPCR ligand binding—HCAR2—psoriasis	0.000589	0.00864	CbGpPWpGaD
Glycine—SHMT2—Folate Metabolism—CRP—psoriasis	0.00058	0.0085	CbGpPWpGaD
Glycine—Pain—Clobetasol propionate—psoriasis	0.000544	0.0065	CcSEcCtD
Glycine—GARS—skin of body—psoriasis	0.000542	0.0856	CbGeAlD
Glycine—SHMT2—Folate Metabolism—ICAM1—psoriasis	0.000533	0.00782	CbGpPWpGaD
Glycine—PIPOX—tendon—psoriasis	0.000533	0.0841	CbGeAlD
Glycine—ALAS1—Organelle biogenesis and maintenance—CARM1—psoriasis	0.000521	0.00764	CbGpPWpGaD
Glycine—GCAT—tendon—psoriasis	0.000517	0.0816	CbGeAlD
Glycine—GARS—Gene Expression—TARS—psoriasis	0.000509	0.00746	CbGpPWpGaD
Glycine—Rhinitis—Acitretin—psoriasis	0.000507	0.00605	CcSEcCtD
Glycine—Rhinitis—Fluocinolone Acetonide—psoriasis	0.000505	0.00604	CcSEcCtD
Glycine—GPR18—G alpha (i) signalling events—CCL20—psoriasis	0.000505	0.00741	CbGpPWpGaD
Glycine—Thirst—Mycophenolic acid—psoriasis	0.000505	0.00603	CcSEcCtD
Glycine—Vertigo—Methoxsalen—psoriasis	0.000499	0.00596	CcSEcCtD
Glycine—SHMT2—Vitamin B12 Metabolism—IFNG—psoriasis	0.000498	0.00731	CbGpPWpGaD
Glycine—Pain—Beclomethasone—psoriasis	0.000495	0.00592	CcSEcCtD
Glycine—Pain—Fluocinonide—psoriasis	0.000491	0.00586	CcSEcCtD
Glycine—Coma—Cyclosporine—psoriasis	0.000489	0.00585	CcSEcCtD
Glycine—Visual impairment—Acitretin—psoriasis	0.000487	0.00582	CcSEcCtD
Glycine—Visual impairment—Fluocinolone Acetonide—psoriasis	0.000486	0.0058	CcSEcCtD
Glycine—Hyponatraemia—Mycophenolic acid—psoriasis	0.000482	0.00576	CcSEcCtD
Glycine—SHMT2—skin of body—psoriasis	0.000471	0.0745	CbGeAlD
Glycine—Hypersensitivity—Clobetasol propionate—psoriasis	0.000469	0.0056	CcSEcCtD
Glycine—SLC6A9—SLC-mediated transmembrane transport—CP—psoriasis	0.000466	0.00684	CbGpPWpGaD
Glycine—SLC6A5—SLC-mediated transmembrane transport—CP—psoriasis	0.000466	0.00684	CbGpPWpGaD
Glycine—AGXT2—Nucleotide metabolism—CAT—psoriasis	0.000462	0.00677	CbGpPWpGaD
Glycine—Encephalopathy—Methotrexate—psoriasis	0.000461	0.00551	CcSEcCtD
Glycine—Urticaria—Beclomethasone—psoriasis	0.00046	0.0055	CcSEcCtD
Glycine—Urinary retention—Mycophenolic acid—psoriasis	0.000457	0.00546	CcSEcCtD
Glycine—Chills—Acitretin—psoriasis	0.000454	0.00542	CcSEcCtD
Glycine—ALAS1—tendon—psoriasis	0.000453	0.0715	CbGeAlD
Glycine—Oedema—Methoxsalen—psoriasis	0.000453	0.00541	CcSEcCtD
Glycine—Dehydration—Mycophenolic acid—psoriasis	0.000447	0.00534	CcSEcCtD
Glycine—Polyuria—Cyclosporine—psoriasis	0.000443	0.00529	CcSEcCtD
Glycine—Thrombophlebitis—Mycophenolate mofetil—psoriasis	0.000438	0.00523	CcSEcCtD
Glycine—ALAS1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000438	0.00643	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—CAT—psoriasis	0.00043	0.00631	CbGpPWpGaD
Glycine—Convulsion—Calcitriol—psoriasis	0.000429	0.00512	CcSEcCtD
Glycine—Back pain—Acitretin—psoriasis	0.000426	0.00508	CcSEcCtD
Glycine—Back pain—Fluocinolone Acetonide—psoriasis	0.000424	0.00507	CcSEcCtD
Glycine—Hypotension—Methoxsalen—psoriasis	0.000423	0.00506	CcSEcCtD
Glycine—Hypersensitivity—Fluocinonide—psoriasis	0.000423	0.00505	CcSEcCtD
Glycine—Lung disorder—Methotrexate—psoriasis	0.000418	0.00499	CcSEcCtD
Glycine—Vision blurred—Acitretin—psoriasis	0.000415	0.00495	CcSEcCtD
Glycine—SHMT2—Vitamin B12 Metabolism—NFKB1—psoriasis	0.000415	0.00608	CbGpPWpGaD
Glycine—Vision blurred—Fluocinolone Acetonide—psoriasis	0.000413	0.00494	CcSEcCtD
Glycine—GARS—tendon—psoriasis	0.000412	0.0651	CbGeAlD
Glycine—Visual disturbance—Cyclosporine—psoriasis	0.00041	0.0049	CcSEcCtD
Glycine—Thrombophlebitis—Prednisolone—psoriasis	0.000409	0.00488	CcSEcCtD
Glycine—SHMT2—Folate Metabolism—IFNG—psoriasis	0.000405	0.00595	CbGpPWpGaD
Glycine—Angina pectoris—Mycophenolic acid—psoriasis	0.000404	0.00483	CcSEcCtD
Glycine—GPR18—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000402	0.00589	CbGpPWpGaD
Glycine—Visual disturbance—Mycophenolate mofetil—psoriasis	0.0004	0.00478	CcSEcCtD
Glycine—Thrombophlebitis—Hydrocortisone—psoriasis	0.000399	0.00477	CcSEcCtD
Glycine—Thirst—Mycophenolate mofetil—psoriasis	0.000398	0.00476	CcSEcCtD
Glycine—SLC32A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000396	0.00581	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—IL4—psoriasis	0.000395	0.0058	CbGpPWpGaD
Glycine—Vertigo—Fluocinolone Acetonide—psoriasis	0.000394	0.00471	CcSEcCtD
Glycine—Dizziness—Beclomethasone—psoriasis	0.000383	0.00457	CcSEcCtD
Glycine—Hyponatraemia—Mycophenolate mofetil—psoriasis	0.000381	0.00455	CcSEcCtD
Glycine—Dizziness—Fluocinonide—psoriasis	0.000379	0.00453	CcSEcCtD
Glycine—Thrombophlebitis—Triamcinolone—psoriasis	0.000376	0.00449	CcSEcCtD
Glycine—Visual disturbance—Prednisolone—psoriasis	0.000373	0.00446	CcSEcCtD
Glycine—Urinary retention—Mycophenolate mofetil—psoriasis	0.000361	0.00431	CcSEcCtD
Glycine—Urticaria—Methoxsalen—psoriasis	0.00036	0.0043	CcSEcCtD
Glycine—Oedema—Acitretin—psoriasis	0.000359	0.00429	CcSEcCtD
Glycine—SHMT2—tendon—psoriasis	0.000359	0.0567	CbGeAlD
Glycine—Oedema—Fluocinolone Acetonide—psoriasis	0.000358	0.00428	CcSEcCtD
Glycine—Chills—Hydroxyurea—psoriasis	0.000356	0.00425	CcSEcCtD
Glycine—Dehydration—Mycophenolate mofetil—psoriasis	0.000353	0.00421	CcSEcCtD
Glycine—Pain—Calcitriol—psoriasis	0.000345	0.00412	CcSEcCtD
Glycine—Nausea—Beclomethasone—psoriasis	0.000344	0.00411	CcSEcCtD
Glycine—SHMT1—Folate Metabolism—CRP—psoriasis	0.000342	0.00501	CbGpPWpGaD
Glycine—Thrombophlebitis—Betamethasone—psoriasis	0.000341	0.00407	CcSEcCtD
Glycine—Thrombophlebitis—Dexamethasone—psoriasis	0.000341	0.00407	CcSEcCtD
Glycine—SHMT2—Folate Metabolism—NFKB1—psoriasis	0.000337	0.00495	CbGpPWpGaD
Glycine—Hypersensitivity—Methoxsalen—psoriasis	0.000334	0.00399	CcSEcCtD
Glycine—Rhinitis—Mycophenolic acid—psoriasis	0.000333	0.00398	CcSEcCtD
Glycine—GPR18—GPCR downstream signaling—HCAR2—psoriasis	0.000333	0.00488	CbGpPWpGaD
Glycine—SHMT1—tendon—psoriasis	0.000327	0.0516	CbGeAlD
Glycine—SHMT2—Vitamin B12 Metabolism—TNF—psoriasis	0.000322	0.00473	CbGpPWpGaD
Glycine—GSS—skin of body—psoriasis	0.000322	0.0509	CbGeAlD
Glycine—Urticaria—Calcitriol—psoriasis	0.000321	0.00383	CcSEcCtD
Glycine—Visual impairment—Mycophenolic acid—psoriasis	0.00032	0.00383	CcSEcCtD
Glycine—Angina pectoris—Mycophenolate mofetil—psoriasis	0.000319	0.00381	CcSEcCtD
Glycine—SHMT1—Folate Metabolism—ICAM1—psoriasis	0.000314	0.00461	CbGpPWpGaD
Glycine—Visual disturbance—Betamethasone—psoriasis	0.000311	0.00372	CcSEcCtD
Glycine—Visual disturbance—Dexamethasone—psoriasis	0.000311	0.00372	CcSEcCtD
Glycine—Pain—Acitretin—psoriasis	0.000307	0.00367	CcSEcCtD
Glycine—Pain—Fluocinolone Acetonide—psoriasis	0.000306	0.00366	CcSEcCtD
Glycine—GPR18—GPCR ligand binding—CCL20—psoriasis	0.000306	0.00449	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—HCAR2—psoriasis	0.000302	0.00443	CbGpPWpGaD
Glycine—ALAS2—Metabolism—NDUFA5—psoriasis	0.0003	0.0044	CbGpPWpGaD
Glycine—Dizziness—Methoxsalen—psoriasis	0.000299	0.00358	CcSEcCtD
Glycine—Convulsion—Hydroxyurea—psoriasis	0.000299	0.00358	CcSEcCtD
Glycine—Chills—Mycophenolic acid—psoriasis	0.000298	0.00356	CcSEcCtD
Glycine—Hypersensitivity—Calcitriol—psoriasis	0.000297	0.00355	CcSEcCtD
Glycine—Thrombophlebitis—Prednisone—psoriasis	0.000297	0.00355	CcSEcCtD
Glycine—Urticaria—Acitretin—psoriasis	0.000285	0.00341	CcSEcCtD
Glycine—Oedema—Hydroxyurea—psoriasis	0.000282	0.00337	CcSEcCtD
Glycine—GRIN2A—tendon—psoriasis	0.00028	0.0443	CbGeAlD
Glycine—Back pain—Mycophenolic acid—psoriasis	0.00028	0.00334	CcSEcCtD
Glycine—SLC36A1—tendon—psoriasis	0.000279	0.044	CbGeAlD
Glycine—Diarrhoea—Calcitriol—psoriasis	0.000276	0.0033	CcSEcCtD
Glycine—Vision blurred—Mycophenolic acid—psoriasis	0.000273	0.00326	CcSEcCtD
Glycine—Coma—Methotrexate—psoriasis	0.00027	0.00323	CcSEcCtD
Glycine—ALAS1—PPARA activates gene expression—PPARG—psoriasis	0.00027	0.00397	CbGpPWpGaD
Glycine—Rhinitis—Cyclosporine—psoriasis	0.00027	0.00322	CcSEcCtD
Glycine—Nausea—Methoxsalen—psoriasis	0.000269	0.00321	CcSEcCtD
Glycine—ALAS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000265	0.00388	CbGpPWpGaD
Glycine—Hypersensitivity—Acitretin—psoriasis	0.000265	0.00316	CcSEcCtD
Glycine—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000264	0.00315	CcSEcCtD
Glycine—Rhinitis—Mycophenolate mofetil—psoriasis	0.000263	0.00314	CcSEcCtD
Glycine—SHMT2—Folate Metabolism—TNF—psoriasis	0.000262	0.00385	CbGpPWpGaD
Glycine—SHMT2—Vitamin B12 Metabolism—IL6—psoriasis	0.00026	0.00382	CbGpPWpGaD
Glycine—Vertigo—Mycophenolic acid—psoriasis	0.00026	0.00311	CcSEcCtD
Glycine—Visual impairment—Cyclosporine—psoriasis	0.000259	0.0031	CcSEcCtD
Glycine—Vomiting—Calcitriol—psoriasis	0.000257	0.00307	CcSEcCtD
Glycine—ALAS2—Metabolism—CYP2S1—psoriasis	0.000255	0.00374	CbGpPWpGaD
Glycine—Visual impairment—Mycophenolate mofetil—psoriasis	0.000253	0.00302	CcSEcCtD
Glycine—Convulsion—Mycophenolic acid—psoriasis	0.000251	0.00299	CcSEcCtD
Glycine—Thrombophlebitis—Methotrexate—psoriasis	0.000248	0.00296	CcSEcCtD
Glycine—Diarrhoea—Acitretin—psoriasis	0.000246	0.00294	CcSEcCtD
Glycine—GSS—tendon—psoriasis	0.000245	0.0387	CbGeAlD
Glycine—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000245	0.00293	CcSEcCtD
Glycine—Polyuria—Methotrexate—psoriasis	0.000245	0.00292	CcSEcCtD
Glycine—Chills—Cyclosporine—psoriasis	0.000241	0.00288	CcSEcCtD
Glycine—Pain—Hydroxyurea—psoriasis	0.000241	0.00288	CcSEcCtD
Glycine—Nausea—Calcitriol—psoriasis	0.00024	0.00286	CcSEcCtD
Glycine—SHMT1—Folate Metabolism—IFNG—psoriasis	0.000239	0.0035	CbGpPWpGaD
Glycine—Dizziness—Acitretin—psoriasis	0.000237	0.00284	CcSEcCtD
Glycine—SLC6A5—Transmembrane transport of small molecules—CP—psoriasis	0.000237	0.00347	CbGpPWpGaD
Glycine—SLC6A9—Transmembrane transport of small molecules—CP—psoriasis	0.000237	0.00347	CbGpPWpGaD
Glycine—Dizziness—Fluocinolone Acetonide—psoriasis	0.000237	0.00283	CcSEcCtD
Glycine—Oedema—Mycophenolic acid—psoriasis	0.000236	0.00282	CcSEcCtD
Glycine—Visual impairment—Prednisolone—psoriasis	0.000236	0.00282	CcSEcCtD
Glycine—Chills—Mycophenolate mofetil—psoriasis	0.000235	0.00281	CcSEcCtD
Glycine—SHMT2—Folate Metabolism—TP53—psoriasis	0.000231	0.00339	CbGpPWpGaD
Glycine—Tachycardia—Mycophenolic acid—psoriasis	0.00023	0.00275	CcSEcCtD
Glycine—Vomiting—Acitretin—psoriasis	0.000228	0.00273	CcSEcCtD
Glycine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000228	0.00272	CcSEcCtD
Glycine—SLC36A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000228	0.00334	CbGpPWpGaD
Glycine—GRIN2C—Alzheimers Disease—APOE—psoriasis	0.000227	0.00333	CbGpPWpGaD
Glycine—GLYAT—Metabolism—NDUFA5—psoriasis	0.000227	0.00333	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—NDUFA5—psoriasis	0.000227	0.00333	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—NDUFA5—psoriasis	0.000227	0.00333	CbGpPWpGaD
Glycine—GATM—Metabolism—NDUFA5—psoriasis	0.000227	0.00333	CbGpPWpGaD
Glycine—Visual disturbance—Methotrexate—psoriasis	0.000227	0.00271	CcSEcCtD
Glycine—SLC6A5—Transmembrane transport of small molecules—CARM1—psoriasis	0.000226	0.00331	CbGpPWpGaD
Glycine—SLC6A9—Transmembrane transport of small molecules—CARM1—psoriasis	0.000226	0.00331	CbGpPWpGaD
Glycine—Rhinitis—Triamcinolone—psoriasis	0.000226	0.00269	CcSEcCtD
Glycine—Back pain—Mycophenolate mofetil—psoriasis	0.000221	0.00264	CcSEcCtD
Glycine—Hypotension—Mycophenolic acid—psoriasis	0.000221	0.00264	CcSEcCtD
Glycine—Vision blurred—Cyclosporine—psoriasis	0.000221	0.00264	CcSEcCtD
Glycine—BAAT—Metabolism—NDUFA5—psoriasis	0.000217	0.00318	CbGpPWpGaD
Glycine—Nausea—Acitretin—psoriasis	0.000213	0.00255	CcSEcCtD
Glycine—Nausea—Fluocinolone Acetonide—psoriasis	0.000213	0.00254	CcSEcCtD
Glycine—SHMT2—Folate Metabolism—IL6—psoriasis	0.000212	0.00311	CbGpPWpGaD
Glycine—Vertigo—Cyclosporine—psoriasis	0.00021	0.00251	CcSEcCtD
Glycine—Hypersensitivity—Hydroxyurea—psoriasis	0.000208	0.00248	CcSEcCtD
Glycine—Vertigo—Mycophenolate mofetil—psoriasis	0.000205	0.00245	CcSEcCtD
Glycine—Convulsion—Cyclosporine—psoriasis	0.000203	0.00242	CcSEcCtD
Glycine—BAAT—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000202	0.00296	CbGpPWpGaD
Glycine—Pain—Mycophenolic acid—psoriasis	0.000202	0.00241	CcSEcCtD
Glycine—GLRA3—Transmembrane transport of small molecules—CP—psoriasis	0.000201	0.00295	CbGpPWpGaD
Glycine—SLC32A1—Transmembrane transport of small molecules—CP—psoriasis	0.000201	0.00295	CbGpPWpGaD
Glycine—GLRA2—Transmembrane transport of small molecules—CP—psoriasis	0.000201	0.00295	CbGpPWpGaD
Glycine—Vision blurred—Prednisolone—psoriasis	0.000201	0.0024	CcSEcCtD
Glycine—SHMT1—Folate Metabolism—NFKB1—psoriasis	0.000199	0.00292	CbGpPWpGaD
Glycine—Convulsion—Mycophenolate mofetil—psoriasis	0.000198	0.00236	CcSEcCtD
Glycine—Visual impairment—Betamethasone—psoriasis	0.000197	0.00235	CcSEcCtD
Glycine—Visual impairment—Dexamethasone—psoriasis	0.000197	0.00235	CcSEcCtD
Glycine—ALAS1—Budesonide—Clobetasol propionate—psoriasis	0.000195	0.0405	CbGdCrCtD
Glycine—GLYATL2—Metabolism—CYP2S1—psoriasis	0.000193	0.00283	CbGpPWpGaD
Glycine—GATM—Metabolism—CYP2S1—psoriasis	0.000193	0.00283	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—CYP2S1—psoriasis	0.000193	0.00283	CbGpPWpGaD
Glycine—GLYAT—Metabolism—CYP2S1—psoriasis	0.000193	0.00283	CbGpPWpGaD
Glycine—AGXT—Metabolism—NDUFA5—psoriasis	0.000193	0.00283	CbGpPWpGaD
Glycine—Diarrhoea—Hydroxyurea—psoriasis	0.000193	0.0023	CcSEcCtD
Glycine—GLRA3—Transmembrane transport of small molecules—CARM1—psoriasis	0.000192	0.00282	CbGpPWpGaD
Glycine—GLRA2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000192	0.00282	CbGpPWpGaD
Glycine—SLC32A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000192	0.00282	CbGpPWpGaD
Glycine—Vertigo—Prednisolone—psoriasis	0.000191	0.00229	CcSEcCtD
Glycine—Oedema—Cyclosporine—psoriasis	0.000191	0.00228	CcSEcCtD
Glycine—Back pain—Triamcinolone—psoriasis	0.000189	0.00226	CcSEcCtD
Glycine—ALAS1—Metabolism—NDUFA5—psoriasis	0.000187	0.00274	CbGpPWpGaD
Glycine—Vertigo—Hydrocortisone—psoriasis	0.000187	0.00223	CcSEcCtD
Glycine—Dizziness—Hydroxyurea—psoriasis	0.000186	0.00223	CcSEcCtD
Glycine—Oedema—Mycophenolate mofetil—psoriasis	0.000186	0.00223	CcSEcCtD
Glycine—Convulsion—Prednisolone—psoriasis	0.000185	0.0022	CcSEcCtD
Glycine—BAAT—Metabolism—CYP2S1—psoriasis	0.000184	0.0027	CbGpPWpGaD
Glycine—ALAS1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000182	0.00267	CbGpPWpGaD
Glycine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000182	0.00217	CcSEcCtD
Glycine—Convulsion—Hydrocortisone—psoriasis	0.00018	0.00215	CcSEcCtD
Glycine—SLC16A10—tendon—psoriasis	0.00018	0.0284	CbGeAlD
Glycine—Vomiting—Hydroxyurea—psoriasis	0.000179	0.00214	CcSEcCtD
Glycine—GPR18—Signaling Pathways—HCAR2—psoriasis	0.000179	0.00262	CbGpPWpGaD
Glycine—Vertigo—Triamcinolone—psoriasis	0.000176	0.0021	CcSEcCtD
Glycine—ALAS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000174	0.00256	CbGpPWpGaD
Glycine—Hypotension—Mycophenolate mofetil—psoriasis	0.000174	0.00208	CcSEcCtD
Glycine—Oedema—Prednisolone—psoriasis	0.000174	0.00208	CcSEcCtD
Glycine—GRIN2A—Alzheimers Disease—APOE—psoriasis	0.000173	0.00254	CbGpPWpGaD
Glycine—GPR18—GPCR downstream signaling—CCL20—psoriasis	0.000173	0.00254	CbGpPWpGaD
Glycine—Oedema—Hydrocortisone—psoriasis	0.00017	0.00203	CcSEcCtD
Glycine—Convulsion—Triamcinolone—psoriasis	0.00017	0.00203	CcSEcCtD
Glycine—Tachycardia—Prednisolone—psoriasis	0.00017	0.00203	CcSEcCtD
Glycine—Nausea—Hydroxyurea—psoriasis	0.000167	0.002	CcSEcCtD
Glycine—Tachycardia—Hydrocortisone—psoriasis	0.000166	0.00198	CcSEcCtD
Glycine—AGXT2—Metabolism—NDUFA5—psoriasis	0.000164	0.00241	CbGpPWpGaD
Glycine—AGXT—Metabolism—CYP2S1—psoriasis	0.000164	0.00241	CbGpPWpGaD
Glycine—GLRB—Transmembrane transport of small molecules—CP—psoriasis	0.000164	0.00241	CbGpPWpGaD
Glycine—Pain—Cyclosporine—psoriasis	0.000163	0.00195	CcSEcCtD
Glycine—Diarrhoea—Mycophenolic acid—psoriasis	0.000162	0.00193	CcSEcCtD
Glycine—GARS—Gene Expression—CARM1—psoriasis	0.00016	0.00235	CbGpPWpGaD
Glycine—Oedema—Triamcinolone—psoriasis	0.00016	0.00191	CcSEcCtD
Glycine—Vertigo—Betamethasone—psoriasis	0.00016	0.00191	CcSEcCtD
Glycine—Vertigo—Dexamethasone—psoriasis	0.00016	0.00191	CcSEcCtD
Glycine—Pain—Mycophenolate mofetil—psoriasis	0.000159	0.0019	CcSEcCtD
Glycine—ALAS1—Metabolism—CYP2S1—psoriasis	0.000159	0.00233	CbGpPWpGaD
Glycine—Hypotension—Hydrocortisone—psoriasis	0.000159	0.0019	CcSEcCtD
Glycine—GPR18—Signaling by GPCR—CCL20—psoriasis	0.000157	0.0023	CbGpPWpGaD
Glycine—GLRB—Transmembrane transport of small molecules—CARM1—psoriasis	0.000157	0.0023	CbGpPWpGaD
Glycine—Dizziness—Mycophenolic acid—psoriasis	0.000156	0.00187	CcSEcCtD
Glycine—ALAS1—Budesonide—Fluocinonide—psoriasis	0.000156	0.0324	CbGdCrCtD
Glycine—ALAS1—Budesonide—Beclomethasone—psoriasis	0.000156	0.0324	CbGdCrCtD
Glycine—Tachycardia—Triamcinolone—psoriasis	0.000156	0.00186	CcSEcCtD
Glycine—GPR18—Signaling Pathways—TAGAP—psoriasis	0.000155	0.00227	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—TNF—psoriasis	0.000155	0.00227	CbGpPWpGaD
Glycine—Convulsion—Betamethasone—psoriasis	0.000154	0.00184	CcSEcCtD
Glycine—Convulsion—Dexamethasone—psoriasis	0.000154	0.00184	CcSEcCtD
Glycine—Urticaria—Cyclosporine—psoriasis	0.000152	0.00181	CcSEcCtD
Glycine—ALAS1—Budesonide—Fluocinolone Acetonide—psoriasis	0.000152	0.0315	CbGdCrCtD
Glycine—Vomiting—Mycophenolic acid—psoriasis	0.00015	0.00179	CcSEcCtD
Glycine—Pain—Prednisolone—psoriasis	0.000149	0.00178	CcSEcCtD
Glycine—Urticaria—Mycophenolate mofetil—psoriasis	0.000148	0.00177	CcSEcCtD
Glycine—Vision blurred—Prednisone—psoriasis	0.000146	0.00174	CcSEcCtD
Glycine—Pain—Hydrocortisone—psoriasis	0.000145	0.00173	CcSEcCtD
Glycine—Oedema—Betamethasone—psoriasis	0.000145	0.00173	CcSEcCtD
Glycine—Oedema—Dexamethasone—psoriasis	0.000145	0.00173	CcSEcCtD
Glycine—Visual impairment—Methotrexate—psoriasis	0.000143	0.00171	CcSEcCtD
Glycine—Tachycardia—Betamethasone—psoriasis	0.000142	0.00169	CcSEcCtD
Glycine—Tachycardia—Dexamethasone—psoriasis	0.000142	0.00169	CcSEcCtD
Glycine—Hypersensitivity—Cyclosporine—psoriasis	0.000141	0.00168	CcSEcCtD
Glycine—Nausea—Mycophenolic acid—psoriasis	0.00014	0.00168	CcSEcCtD
Glycine—AGXT2—Metabolism—CYP2S1—psoriasis	0.00014	0.00205	CbGpPWpGaD
Glycine—Vertigo—Prednisone—psoriasis	0.000139	0.00166	CcSEcCtD
Glycine—SLC16A10—SLC-mediated transmembrane transport—CP—psoriasis	0.000138	0.00203	CbGpPWpGaD
Glycine—Urticaria—Prednisolone—psoriasis	0.000138	0.00165	CcSEcCtD
Glycine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000137	0.00164	CcSEcCtD
Glycine—Pain—Triamcinolone—psoriasis	0.000137	0.00163	CcSEcCtD
Glycine—GPR18—G alpha (i) signalling events—CXCL8—psoriasis	0.000136	0.002	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—TP53—psoriasis	0.000136	0.002	CbGpPWpGaD
Glycine—Hypotension—Betamethasone—psoriasis	0.000136	0.00162	CcSEcCtD
Glycine—Hypotension—Dexamethasone—psoriasis	0.000136	0.00162	CcSEcCtD
Glycine—Urticaria—Hydrocortisone—psoriasis	0.000135	0.00161	CcSEcCtD
Glycine—Convulsion—Prednisone—psoriasis	0.000134	0.0016	CcSEcCtD
Glycine—SHMT1—Metabolism—NDUFA5—psoriasis	0.000134	0.00196	CbGpPWpGaD
Glycine—Chills—Methotrexate—psoriasis	0.000133	0.00159	CcSEcCtD
Glycine—Diarrhoea—Cyclosporine—psoriasis	0.000131	0.00156	CcSEcCtD
Glycine—GSS—Metabolism—NDUFA5—psoriasis	0.00013	0.00191	CbGpPWpGaD
Glycine—GLRA1—Transmembrane transport of small molecules—CP—psoriasis	0.00013	0.0019	CbGpPWpGaD
Glycine—Hypersensitivity—Prednisolone—psoriasis	0.000128	0.00153	CcSEcCtD
Glycine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000127	0.00152	CcSEcCtD
Glycine—Urticaria—Triamcinolone—psoriasis	0.000127	0.00152	CcSEcCtD
Glycine—Dizziness—Cyclosporine—psoriasis	0.000126	0.00151	CcSEcCtD
Glycine—Oedema—Prednisone—psoriasis	0.000126	0.00151	CcSEcCtD
Glycine—Back pain—Methotrexate—psoriasis	0.000125	0.00149	CcSEcCtD
Glycine—Hypersensitivity—Hydrocortisone—psoriasis	0.000125	0.00149	CcSEcCtD
Glycine—SHMT1—Folate Metabolism—IL6—psoriasis	0.000125	0.00183	CbGpPWpGaD
Glycine—ALAS2—Metabolism—CARM1—psoriasis	0.000124	0.00183	CbGpPWpGaD
Glycine—Pain—Betamethasone—psoriasis	0.000124	0.00148	CcSEcCtD
Glycine—Pain—Dexamethasone—psoriasis	0.000124	0.00148	CcSEcCtD
Glycine—GLRA1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000124	0.00182	CbGpPWpGaD
Glycine—Tachycardia—Prednisone—psoriasis	0.000123	0.00147	CcSEcCtD
Glycine—Dizziness—Mycophenolate mofetil—psoriasis	0.000123	0.00147	CcSEcCtD
Glycine—Vision blurred—Methotrexate—psoriasis	0.000122	0.00146	CcSEcCtD
Glycine—Vomiting—Cyclosporine—psoriasis	0.000121	0.00145	CcSEcCtD
Glycine—ALAS1—Betamethasone—Clobetasol propionate—psoriasis	0.000119	0.0248	CbGdCrCtD
Glycine—ALAS1—Dexamethasone—Clobetasol propionate—psoriasis	0.000119	0.0248	CbGdCrCtD
Glycine—Vomiting—Mycophenolate mofetil—psoriasis	0.000118	0.00142	CcSEcCtD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	0.000118	0.00173	CbGpPWpGaD
Glycine—Hypersensitivity—Triamcinolone—psoriasis	0.000118	0.00141	CcSEcCtD
Glycine—Vertigo—Methotrexate—psoriasis	0.000116	0.00139	CcSEcCtD
Glycine—Diarrhoea—Hydrocortisone—psoriasis	0.000116	0.00139	CcSEcCtD
Glycine—SLC36A1—Transmembrane transport of small molecules—CP—psoriasis	0.000116	0.0017	CbGpPWpGaD
Glycine—Urticaria—Dexamethasone—psoriasis	0.000115	0.00138	CcSEcCtD
Glycine—Urticaria—Betamethasone—psoriasis	0.000115	0.00138	CcSEcCtD
Glycine—Dizziness—Prednisolone—psoriasis	0.000115	0.00137	CcSEcCtD
Glycine—SHMT1—Metabolism—CYP2S1—psoriasis	0.000114	0.00167	CbGpPWpGaD
Glycine—Nausea—Cyclosporine—psoriasis	0.000113	0.00136	CcSEcCtD
Glycine—Dizziness—Hydrocortisone—psoriasis	0.000112	0.00134	CcSEcCtD
Glycine—Convulsion—Methotrexate—psoriasis	0.000112	0.00134	CcSEcCtD
Glycine—GSS—Metabolism—CYP2S1—psoriasis	0.000111	0.00163	CbGpPWpGaD
Glycine—Nausea—Mycophenolate mofetil—psoriasis	0.000111	0.00132	CcSEcCtD
Glycine—SLC36A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.00011	0.00162	CbGpPWpGaD
Glycine—GPR18—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000108	0.00159	CbGpPWpGaD
Glycine—Vomiting—Hydrocortisone—psoriasis	0.000108	0.00129	CcSEcCtD
Glycine—Dizziness—Triamcinolone—psoriasis	0.000106	0.00126	CcSEcCtD
Glycine—GRIN2C—Alzheimers Disease—TNF—psoriasis	0.000105	0.00154	CbGpPWpGaD
Glycine—Nausea—Prednisolone—psoriasis	0.000103	0.00123	CcSEcCtD
Glycine—Vomiting—Triamcinolone—psoriasis	0.000102	0.00121	CcSEcCtD
Glycine—Nausea—Hydrocortisone—psoriasis	0.000101	0.0012	CcSEcCtD
Glycine—Urticaria—Prednisone—psoriasis	0.0001	0.0012	CcSEcCtD
Glycine—Diarrhoea—Betamethasone—psoriasis	9.92e-05	0.00119	CcSEcCtD
Glycine—Diarrhoea—Dexamethasone—psoriasis	9.92e-05	0.00119	CcSEcCtD
Glycine—Hypotension—Methotrexate—psoriasis	9.86e-05	0.00118	CcSEcCtD
Glycine—BAAT—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.65e-05	0.00142	CbGpPWpGaD
Glycine—Dizziness—Dexamethasone—psoriasis	9.59e-05	0.00115	CcSEcCtD
Glycine—Dizziness—Betamethasone—psoriasis	9.59e-05	0.00115	CcSEcCtD
Glycine—GARS—Gene Expression—VDR—psoriasis	9.56e-05	0.0014	CbGpPWpGaD
Glycine—ALAS1—Dexamethasone—Fluocinonide—psoriasis	9.55e-05	0.0198	CbGdCrCtD
Glycine—ALAS1—Betamethasone—Beclomethasone—psoriasis	9.55e-05	0.0198	CbGdCrCtD
Glycine—ALAS1—Dexamethasone—Beclomethasone—psoriasis	9.55e-05	0.0198	CbGdCrCtD
Glycine—ALAS1—Betamethasone—Fluocinonide—psoriasis	9.55e-05	0.0198	CbGdCrCtD
Glycine—Nausea—Triamcinolone—psoriasis	9.49e-05	0.00113	CcSEcCtD
Glycine—GATM—Metabolism—CARM1—psoriasis	9.43e-05	0.00138	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—CARM1—psoriasis	9.43e-05	0.00138	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—CARM1—psoriasis	9.43e-05	0.00138	CbGpPWpGaD
Glycine—GLYAT—Metabolism—CARM1—psoriasis	9.43e-05	0.00138	CbGpPWpGaD
Glycine—Hypersensitivity—Prednisone—psoriasis	9.31e-05	0.00111	CcSEcCtD
Glycine—ALAS1—Dexamethasone—Fluocinolone Acetonide—psoriasis	9.28e-05	0.0193	CbGdCrCtD
Glycine—ALAS1—Betamethasone—Fluocinolone Acetonide—psoriasis	9.28e-05	0.0193	CbGdCrCtD
Glycine—GPR18—Signaling Pathways—CCL20—psoriasis	9.27e-05	0.00136	CbGpPWpGaD
Glycine—GRIN2C—Alzheimers Disease—TP53—psoriasis	9.26e-05	0.00136	CbGpPWpGaD
Glycine—Vomiting—Betamethasone—psoriasis	9.22e-05	0.0011	CcSEcCtD
Glycine—Vomiting—Dexamethasone—psoriasis	9.22e-05	0.0011	CcSEcCtD
Glycine—Pain—Methotrexate—psoriasis	9.03e-05	0.00108	CcSEcCtD
Glycine—BAAT—Metabolism—CARM1—psoriasis	9e-05	0.00132	CbGpPWpGaD
Glycine—Diarrhoea—Prednisone—psoriasis	8.64e-05	0.00103	CcSEcCtD
Glycine—Nausea—Betamethasone—psoriasis	8.62e-05	0.00103	CcSEcCtD
Glycine—Nausea—Dexamethasone—psoriasis	8.62e-05	0.00103	CcSEcCtD
Glycine—BAAT—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.41e-05	0.00123	CbGpPWpGaD
Glycine—Urticaria—Methotrexate—psoriasis	8.39e-05	0.001	CcSEcCtD
Glycine—Dizziness—Prednisone—psoriasis	8.35e-05	0.000998	CcSEcCtD
Glycine—ALAS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.33e-05	0.00122	CbGpPWpGaD
Glycine—GPR18—GPCR ligand binding—CXCL8—psoriasis	8.26e-05	0.00121	CbGpPWpGaD
Glycine—Vomiting—Prednisone—psoriasis	8.03e-05	0.00096	CcSEcCtD
Glycine—GRIN2A—Alzheimers Disease—TNF—psoriasis	8.02e-05	0.00118	CbGpPWpGaD
Glycine—AGXT—Metabolism—CARM1—psoriasis	8.02e-05	0.00118	CbGpPWpGaD
Glycine—Hypersensitivity—Methotrexate—psoriasis	7.78e-05	0.000929	CcSEcCtD
Glycine—ALAS1—Metabolism—CARM1—psoriasis	7.77e-05	0.00114	CbGpPWpGaD
Glycine—ALAS1—Budesonide—Hydrocortisone—psoriasis	7.66e-05	0.0159	CbGdCrCtD
Glycine—ALAS2—Metabolism—CAT—psoriasis	7.65e-05	0.00112	CbGpPWpGaD
Glycine—Nausea—Prednisone—psoriasis	7.5e-05	0.000896	CcSEcCtD
Glycine—ALAS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.26e-05	0.00107	CbGpPWpGaD
Glycine—Diarrhoea—Methotrexate—psoriasis	7.22e-05	0.000863	CcSEcCtD
Glycine—ALAS1—Budesonide—Dexamethasone—psoriasis	7.11e-05	0.0148	CbGdCrCtD
Glycine—ALAS1—Budesonide—Betamethasone—psoriasis	7.11e-05	0.0148	CbGdCrCtD
Glycine—GRIN2A—Alzheimers Disease—TP53—psoriasis	7.07e-05	0.00104	CbGpPWpGaD
Glycine—SLC16A10—Transmembrane transport of small molecules—CP—psoriasis	7.03e-05	0.00103	CbGpPWpGaD
Glycine—Dizziness—Methotrexate—psoriasis	6.98e-05	0.000834	CcSEcCtD
Glycine—ALAS1—Budesonide—Triamcinolone—psoriasis	6.95e-05	0.0145	CbGdCrCtD
Glycine—AGXT2—Metabolism—CARM1—psoriasis	6.82e-05	0.001	CbGpPWpGaD
Glycine—Vomiting—Methotrexate—psoriasis	6.71e-05	0.000802	CcSEcCtD
Glycine—SLC16A10—Transmembrane transport of small molecules—CARM1—psoriasis	6.71e-05	0.000984	CbGpPWpGaD
Glycine—GARS—Gene Expression—PPARG—psoriasis	6.66e-05	0.000977	CbGpPWpGaD
Glycine—ALAS1—Budesonide—Prednisone—psoriasis	6.6e-05	0.0137	CbGdCrCtD
Glycine—ALAS1—Budesonide—Prednisolone—psoriasis	6.44e-05	0.0134	CbGdCrCtD
Glycine—Nausea—Methotrexate—psoriasis	6.27e-05	0.000749	CcSEcCtD
Glycine—ALAS2—Metabolism—APOE—psoriasis	5.95e-05	0.000873	CbGpPWpGaD
Glycine—GATM—Metabolism—CAT—psoriasis	5.8e-05	0.000851	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—CAT—psoriasis	5.8e-05	0.000851	CbGpPWpGaD
Glycine—GLYAT—Metabolism—CAT—psoriasis	5.8e-05	0.000851	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—CAT—psoriasis	5.8e-05	0.000851	CbGpPWpGaD
Glycine—SHMT1—Metabolism—CARM1—psoriasis	5.56e-05	0.000816	CbGpPWpGaD
Glycine—BAAT—Metabolism—CAT—psoriasis	5.53e-05	0.000812	CbGpPWpGaD
Glycine—GSS—Metabolism—CARM1—psoriasis	5.42e-05	0.000795	CbGpPWpGaD
Glycine—ALAS2—Metabolism—PPARG—psoriasis	5.18e-05	0.00076	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—SOCS1—psoriasis	5.11e-05	0.000749	CbGpPWpGaD
Glycine—AGXT—Metabolism—CAT—psoriasis	4.93e-05	0.000724	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—TYK2—psoriasis	4.87e-05	0.000714	CbGpPWpGaD
Glycine—ALAS1—Metabolism—CAT—psoriasis	4.78e-05	0.000701	CbGpPWpGaD
Glycine—ALAS1—Dexamethasone—Hydrocortisone—psoriasis	4.69e-05	0.00974	CbGdCrCtD
Glycine—ALAS1—Betamethasone—Hydrocortisone—psoriasis	4.69e-05	0.00974	CbGdCrCtD
Glycine—GPR18—GPCR downstream signaling—CXCL8—psoriasis	4.67e-05	0.000685	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—APOE—psoriasis	4.51e-05	0.000661	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—APOE—psoriasis	4.51e-05	0.000661	CbGpPWpGaD
Glycine—GLYAT—Metabolism—APOE—psoriasis	4.51e-05	0.000661	CbGpPWpGaD
Glycine—GATM—Metabolism—APOE—psoriasis	4.51e-05	0.000661	CbGpPWpGaD
Glycine—ALAS1—Betamethasone—Dexamethasone—psoriasis	4.35e-05	0.00905	CbGdCrCtD
Glycine—ALAS1—Dexamethasone—Betamethasone—psoriasis	4.35e-05	0.00905	CbGdCrCtD
Glycine—BAAT—Metabolism—APOE—psoriasis	4.3e-05	0.000631	CbGpPWpGaD
Glycine—ALAS1—Betamethasone—Triamcinolone—psoriasis	4.25e-05	0.00884	CbGdCrCtD
Glycine—ALAS1—Dexamethasone—Triamcinolone—psoriasis	4.25e-05	0.00884	CbGdCrCtD
Glycine—GPR18—Signaling by GPCR—CXCL8—psoriasis	4.24e-05	0.000622	CbGpPWpGaD
Glycine—AGXT2—Metabolism—CAT—psoriasis	4.19e-05	0.000615	CbGpPWpGaD
Glycine—ALAS1—Dexamethasone—Prednisone—psoriasis	4.03e-05	0.00839	CbGdCrCtD
Glycine—ALAS1—Betamethasone—Prednisone—psoriasis	4.03e-05	0.00839	CbGdCrCtD
Glycine—ALAS1—Betamethasone—Prednisolone—psoriasis	3.94e-05	0.00819	CbGdCrCtD
Glycine—ALAS1—Dexamethasone—Prednisolone—psoriasis	3.94e-05	0.00819	CbGdCrCtD
Glycine—GATM—Metabolism—PPARG—psoriasis	3.93e-05	0.000576	CbGpPWpGaD
Glycine—GLYAT—Metabolism—PPARG—psoriasis	3.93e-05	0.000576	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—PPARG—psoriasis	3.93e-05	0.000576	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—PPARG—psoriasis	3.93e-05	0.000576	CbGpPWpGaD
Glycine—AGXT—Metabolism—APOE—psoriasis	3.83e-05	0.000562	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—LEP—psoriasis	3.77e-05	0.000553	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—APOE—psoriasis	3.77e-05	0.000553	CbGpPWpGaD
Glycine—BAAT—Metabolism—PPARG—psoriasis	3.75e-05	0.00055	CbGpPWpGaD
Glycine—ALAS1—Metabolism—APOE—psoriasis	3.71e-05	0.000545	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—NFKBIA—psoriasis	3.51e-05	0.000515	CbGpPWpGaD
Glycine—SHMT1—Metabolism—CAT—psoriasis	3.42e-05	0.000502	CbGpPWpGaD
Glycine—SHMT1—Disease—HLA-A—psoriasis	3.4e-05	0.000499	CbGpPWpGaD
Glycine—AGXT—Metabolism—PPARG—psoriasis	3.34e-05	0.00049	CbGpPWpGaD
Glycine—GSS—Metabolism—CAT—psoriasis	3.33e-05	0.000489	CbGpPWpGaD
Glycine—AGXT2—Metabolism—APOE—psoriasis	3.26e-05	0.000478	CbGpPWpGaD
Glycine—ALAS1—Metabolism—PPARG—psoriasis	3.23e-05	0.000474	CbGpPWpGaD
Glycine—SHMT1—Disease—APOE—psoriasis	3.17e-05	0.000465	CbGpPWpGaD
Glycine—SHMT1—Disease—NOS2—psoriasis	2.96e-05	0.000434	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—TYK2—psoriasis	2.88e-05	0.000422	CbGpPWpGaD
Glycine—AGXT2—Metabolism—PPARG—psoriasis	2.84e-05	0.000416	CbGpPWpGaD
Glycine—SHMT1—Metabolism—APOE—psoriasis	2.66e-05	0.00039	CbGpPWpGaD
Glycine—GSS—Metabolism—APOE—psoriasis	2.59e-05	0.00038	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—CXCL8—psoriasis	2.5e-05	0.000367	CbGpPWpGaD
Glycine—SHMT1—Disease—TYK2—psoriasis	2.42e-05	0.000355	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—IL6—psoriasis	2.38e-05	0.000349	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—JUN—psoriasis	2.33e-05	0.000342	CbGpPWpGaD
Glycine—SHMT1—Metabolism—PPARG—psoriasis	2.31e-05	0.000339	CbGpPWpGaD
Glycine—GSS—Metabolism—PPARG—psoriasis	2.25e-05	0.000331	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—NFKB1—psoriasis	2.24e-05	0.000329	CbGpPWpGaD
Glycine—SHMT1—Disease—CD4—psoriasis	2.19e-05	0.000321	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—VEGFA—psoriasis	2.03e-05	0.000298	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—STAT3—psoriasis	2.01e-05	0.000296	CbGpPWpGaD
Glycine—SHMT1—Disease—STAT3—psoriasis	1.7e-05	0.000249	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—TP53—psoriasis	1.54e-05	0.000226	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—IL6—psoriasis	1.41e-05	0.000206	CbGpPWpGaD
Glycine—SHMT1—Disease—IL6—psoriasis	1.18e-05	0.000174	CbGpPWpGaD
